GH

Guardant Health

NASDAQ

Real-time Quotes | Nasdaq Last Sale

109.80

-0.35

-0.32%

After Hours: 109.80 0 0.00% 16:04 07/30 EDT

OPEN

109.85

PREV CLOSE

110.15

HIGH

112.20

LOW

109.12

VOLUME

511.10K

TURNOVER

52 WEEK HIGH

181.07

52 WEEK LOW

77.69

MARKET CAP

11.10B

P/E (TTM)

-32.5565

Bear of the Day: NeoGenomics (NEO)

Zacks.com · 1d ago

Earnings Preview: Guardant Health (GH) Q2 Earnings Expected to Decline

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks · 2d ago

Guardant Health invests in South Korea AI-powered cancer solutions company

4X-image/iStock via Getty Images Guardant Health ([[GH]] -0.1%) has made a $26M investment in Lunit, a South Korea-based artificial intelligence-powered cancer solutions company. The investment also includes a collaboration between

Seekingalpha · 07/19 15:25

Lunit Reports $26M Strategic Investment From Guardant Health, No Terms Disclosed

Lunit, a leading AI startup in AI-powered cancer solutions, today announced a strategic investment of $26 million from Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company. The deal, which includes

Benzinga · 07/19 13:32

AI Startup Lunit Secures Investment from Guardant Health in a Strategic Funding Round

Lunit, a leading AI startup in AI-powered cancer solutions, today announced a strategic investment of $26 million from Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company.

PR Newswire · 07/19 13:30

Guardant Health Invests $26 Million in Medical Startup Lunit

MT Newswires · 07/19 11:50

Bull of the Day: Exact Sciences (EXAS)

Zacks.com · 07/19 09:20

Carnegie Capital Asset Management, LLC Buys Shoals Technologies Group Inc, Guardant Health Inc, ...

GuruFocus News · 07/16 22:38

Forecast

Actual (USD)

Estimate (USD)

Income StatementMore

Net Income (USD)

YoY (%)

Balance SheetMore

Total Assets (USD)

Total Liabilities (USD)

Debt to Asset (%)

Cash FlowMore

Operating (USD)

YoY (%)

Learn about the latest financial forecast of GH. Analyze the recent business situations of Guardant Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.

Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GH stock price target is 170.08 with a high estimate of 195.00 and a low estimate of 150.00.

EPS

Institutional Holdings

Institutions: 540

Institutional Holdings: 95.34M

% Owned: 94.28%

Shares Outstanding: 101.12M

TypeInstitutionsShares

Increased

139

10.47M

New

1.31M

Decreased

152

6.42M

Sold Out

1.21M

Performance
Asset Allocation
Dividend History

No Data

Industry

Biotechnology & Medical Research

-0.07%

Pharmaceuticals & Medical Research

-0.24%

Key Executives

Chairman/President/Chief Operating Officer/Director

AmirAli Talasaz

Chief Executive Officer/Director

Helmy Eltoukhy

Chief Financial Officer

Michael Bell

Senior Vice President/General Counsel/Secretary

John Saia

Other

Craig Eagle

Other

Michael Wiley

Lead Director/Independent Director

Ian Clark

Independent Director

Vijaya Gadde

Independent Director

Bahija Jallal

Independent Director

Samir Kaul

Independent Director

Stanley Meresman

No Data

All
Financials
Insiders

About GH

Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant360 is a molecular diagnostic test that measures 73 cancer-related genes from circulating tumor deoxyribonucleic acid (ctDNA). Its Guardant360 process includes blood collection, laboratory processing, analysis and reporting. Guardant360 is used for a range of applications, including translational science research and identifying target patient populations, drug development and commercialization post-drug approval.

Webull offers kinds of Guardant Health Inc stock information, including NASDAQ:GH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GH stock methods without spending real money on the virtual paper trading platform.